Medication isn’t the only route to relief. If your adolescent patients are experiencing depression, NeuroStar TMS is a safe and effective in-office treatment as an add-on therapy. NeuroStar uses magnetic pulses to stimulate mood-regulating areas in the brain for those with depression for ages 15 and older. In a clinical study of 1,169 adolescent patients: 78% cited improvement in their depression symptoms 48% showed symptom relief (remission) We’re here to help! Visit the link below to learn more about adding NeuroStar TMS to your patient’s current treatment plan. https://lnkd.in/g24QbUVP
Active Path Mental Health’s Post
More Relevant Posts
-
An evaluation comparing TMS and ECT treatments indicated that TMS, specifically targeting the left DLPFC, achieved a higher remission rate with an 82% response rate. In contrast, ECT showed a response rate ranging from 75% to 83%. rTMS is a non-invasive therapy that does not require hospitalization, unlike ECT. It is favored for managing depression symptoms in patients with Major Depressive Disorder (MDD). For further insights into these treatment options, stay informed with Sebers Medical.
-
-
We are thrilled beyond words to extend a MASSIVE congratulations to MindMed on achieving a groundbreaking milestone today! In a pioneering leap forward, MindMed has unveiled the positive outcomes of their Phase 2b study of MM120 in treating patients with Generalized Anxiety Disorder (GAD). This is not just news; it's a beacon of hope for millions! These compelling results do not merely suggest but robustly validate the immense potential that MM120 harbors in revolutionizing the treatment landscape for a condition that impacts an estimated 10% of U.S. adults. At Segal Trials, our hearts swell with pride for having played a pivotal role in contributing to this top-tier data. Our journey in this partnership has been fueled by a shared vision and relentless dedication to pushing the boundaries of what's possible in psychedelic research. We stand more committed than ever to advancing this exciting field, inspired by the promise that today's achievement holds for the future. Here's to breaking new ground, challenging the status quo, and paving the way for therapies that could transform lives. Together, we are on the cusp of a new era in mental health treatment. Thank you to everyone involved for your hard work, your belief in the cause, and your dedication to making a difference. Let's continue to innovate, inspire, and impact the world positively. The best is yet to come! #MindMed #PsychedelicResearch #InnovationInHealthcare #MentalHealthMatters #GADTreatment #Phase2bSuccess #FutureOfMedicine #SegalTrials
We are thrilled to report that our Phase 2b trial of MM120 in generalized anxiety disorder patients met its key secondary endpoint and maintained a clinically and statistically significantly superior HAM-A reduction compared to placebo after 12 weeks. The outcome was observed after a single oral administration of MM120 in a monitored clinical setting with no additional therapeutic intervention. In the study, 48% of GAD patients achieved remission, a remarkable finding that should provide hope to people living with the burden of severe anxiety. See press release for more information: https://bit.ly/3PaKC3s $MNMD
-
-
Discover the breakthrough findings from controlled clinical trials using TMS for Major Depressive Disorder (MDD). With approximately 1 in 3 patients experiencing complete symptom relief and no side effects associated with antidepressants, TMS offers a promising alternative. Explore the potential of owning your own TMS device at sebersmedical.com
-
-
Medical doctor from Iran University of medical sciences. Masters of public health.researcher.
🎊 Treating obsessive-compulsive disorder often necessitates the use of additional medications alongside the primary treatment. Our recent study explores one such medication. For more information, you can check out "The safety and efficacy of N-acetylcysteine as an augmentation in the treatment of obsessive-compulsive disorder in adults: a systematic review and meta-analysis of randomized clinical trials" at the link provided: https://lnkd.in/dt6PHZR5
-
-
Medication isn’t the only route to relief. If your adolescent is experiencing depression, NeuroStar TMS is a safe and effective in-office treatment as an add-on therapy. NeuroStar uses magnetic pulses to stimulate mood-regulating areas in the brain for those with depression for ages 15 and older. In a clinical study of 1,169 adolescent patients: 78% cited improvement in their depression symptoms* 48% showed symptom relief (remission)* We’re here to help! Call our practice today to learn more about adding NeuroStar TMS to your loved one’s current treatment plan. Visit neurostar.com for full safety and prescribing information. *FDA Clearance K231926 The outcomes reported represent the subset of study patients for which the CGI-S data was reported before and after an acute course of NeuroStar TMS. Patients aged 12 to 21 (average 19.2 ± 1.5) were treated under real-world conditions where patients may have been prescribed concomitant depression treatments including medications. “Measurable relief” was defined as a CGI-S score ≤3 and “complete remission” was defined as a CGI-S score ≤2 at the end of treatment. #NeuroStarProvider #NeuroStarConnects #NeuroStar #NeuroStarSocial
-
Medication isn’t the only route to relief. If your adolescent is experiencing depression, NeuroStar TMS is a safe and effective in-office treatment as an add-on therapy. NeuroStar uses magnetic pulses to stimulate mood-regulating areas in the brain for those with depression for ages 15 and older. In a clinical study of 1,169 adolescent patients: 78% cited improvement in their depression symptoms* 48% showed symptom relief (remission)* We’re here to help! Call our practice today to learn more about adding NeuroStar TMS to your loved one’s current treatment plan. Visit neurostar.com for full safety and prescribing information. *FDA Clearance K231926 The outcomes reported represent the subset of study patients for which the CGI-S data was reported before and after an acute course of NeuroStar TMS. Patients aged 12 to 21 (average 19.2 ± 1.5) were treated under real-world conditions where patients may have been prescribed concomitant depression treatments including medications. “Measurable relief” was defined as a CGI-S score ≤3 and “complete remission” was defined as a CGI-S score ≤2 at the end of treatment. #NeuroStarProvider #NeuroStarConnects #NeuroStar #NeuroStarSocial
-
Business Development, Director of Marketing specializing in Influencer and Thought Leadership, Strategic Partnerships, Blockchain and Emerging Tech-for-Good with a Social Impact lens. Futurism, Forecasting and Fun!
these are major factors
Taking great companies public on global stock exchanges. And, I am on a mission to enhance global wellness and improve treatments for mental health conditions.
The impact of under-representation of women in clinical trials is significant and has resulted in an over-representation of serious adverse events and side effects from prescribed medications in women. Tune into Dr Rachael Sumner, who discusses the issues and the team's approach in newly approved clinical trials for negative mood symptom alleviation in Pre-Menstrual Syndrome (PMS) and Pre-Menstrual Dysphoric Disorder (PMDD).
-
Are you running a clinical trial related to #MyastheniaGravis or other neuromuscular disorders? Reach out so we can share this information with #MG patients. Active trials are shared on our website at https://ow.ly/ryzc50RiAn3. #MGresearch #Research #ClinicalTrial
-
-
President/CEO of Total Insight Psychiatric Services, PLLC; Board Certified Child, Adolescent, and Adult Psychiatrist/Interventional Psychiatrist
Medication isn’t the only route to relief. If your adolescent is experiencing depression, NeuroStar TMS is a safe and effective in-office treatment as an add-on therapy. NeuroStar uses magnetic pulses to stimulate mood-regulating areas in the brain for those with depression for ages 15 and older. In a clinical study of 1,169 adolescent patients: 78% cited improvement in their depression symptoms* 48% showed symptom relief (remission)* Contact Totalinsight.ORG to learn more about adding NeuroStar TMS to your loved one’s current treatment plan. Visit neurostar.com for full safety and prescribing information. *FDA Clearance K231926 The outcomes reported represent the subset of study patients for which the CGI-S data was reported before and after an acute course of NeuroStar TMS. Patients aged 12 to 21 (average 19.2 ± 1.5) were treated under real-world conditions where patients may have been prescribed concomitant depression treatments including medications. “Measurable relief” was defined as a CGI-S score ≤3 and “complete remission” was defined as a CGI-S score ≤2 at the end of treatment. #NeuroStarProvider #TMS
-
10 YEARS EXPERISNCE WITH MANUAL OFF PAGE SEO LINK BUILDING, BACKLINKS Skyrocket Your Google/YouTube Ranking with our Professional Seo Link building, Backlinks Service.
Vigabatrin powder|vigabatrin|INSTRUCTIONS FOR USE - VIGPODER Vigabatrin powder is a medication used primarily in the treatment of epilepsy. Known for its efficacy in controlling seizures, it has become a critical component in the therapeutic arsenal against this neurological disorder. This article will delve into the uses, benefits, and potential side effects of vigabatrin powder, providing a thorough understanding for patients, caregivers, and healthcare professionals. Learn more info. check out here: https://lnkd.in/dpymdxwC
